EP
TARS icon

Essential Partners’s Tarsus Pharmaceuticals TARS Stock Holding History

Essential Partners’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.08K Buy
33
+7
+27% +$447 ﹤0.01% 1956
2026
Q1 		$1.82K Hold
26
– – ﹤0.01% 2046
2025
Q4 		$2.13K Hold
26
– – ﹤0.01% 1776
2025
Q3 		$1.54K Buy
26
+23
+767% +$1.13K ﹤0.01% 1880
2025
Q2 		$122 Buy
+3
New +$135 ﹤0.01% 2039

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Essential Partners's TARS Position: Q2 2026 in Review

Essential Partners increased its Tarsus Pharmaceuticals (TARS) stake by 27% in Q2 2026, buying an estimated $447 and bringing the position to 33 shares worth $2.08K. The position accounts for ﹤0.01% of the portfolio, ranked #1956.

Essential Partners first reported a position in TARS in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.13K in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Essential Partners held 33 shares of Tarsus Pharmaceuticals worth $2.08K as of Q2 2026.
  • Essential Partners bought 7 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $447.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1956 holding.
  • Essential Partners first reported a position in Tarsus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Tarsus Pharmaceuticals position peaked at $2.13K in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.